Medmonitor

Teligent Pharma is recalling five lots of Lidocaine HCl topical solution 4%, 50mL after uncovered super potency. Use of super potent products can result in higher than intended doses of medication. Lidocaine hydrochloride works as a local anesthetic that can relieve pain. An increased lidocaine dose can lead to the development of local anesthetic systemic toxicity, which can cause a number of central nervous system reactions, including death.

Bryant Ranch Prepack is recalling one lot of methocarbamol 500mg tablets, as the bottles labeled as 500mg tablets in fact contain 750mg tablets, and excessive dosing could result in central nervous system depression, which can cause nausea, sedation, fainting, falls, seizures, coma, and death. Methocarbamol, along with rest, physical therapies, and other measures, is used for the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Hospira voluntarily recalled lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection and lot EG8933 of 1% Lidocaine HCl Injection, due to mislabeling whereby a portion of each lot was incorrectly labeled as the other product. Both drugs are indicated for the production of local or regional anesthesia. Using lidocaine 1% instead of bupivacaine 0.5% drug instead could lead to underdose and inadequate pain management, while use of bupivacaine 0.5% instead of lidocaine 1% could lead to overdose, which could cause seizures, respiratory abnormalities, and heart problems.